Drug Detail

Information about BGB324

Generic Name
IND	BGB324
Brand Name (US)
Manufacturer	BerGenBio
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	GIST cell based
Strategy	Block related tumor signal paths
Drug Category	AXL inhibitor

From manufacturer website:
BGB324 is a first-in-class, highly selective, orally bioavailable small molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition (EMT), which is a key driver in immune evasion, drug-resistance and metastasis.

AXL has been suggested as a resistance mechanism in both GIST and CML.